

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207

## **Provisional Stakeholder List**

Consultees	Commentators (no right to submit or
	appeal)
<u>Company</u>	<u>General</u>
Merck Sharp & Dohme	<ul> <li>All Wales Therapeutics and Toxicology</li> </ul>
(pembrolizumab)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Black Health Agency for Equality	Wales
Cancer Black Care	British National Formulary
Cancer Equality	Care Quality Commission
Cancer 52	Department of Health, Social Services
Endometriosis UK	and Public Safety for Northern Ireland
Eve Appeal	Healthcare Improvement Scotland
Go Girls	Medicines and Healthcare products
Helen Rollason Cancer Charity	Regulatory Agency
<ul> <li>Independent Cancer Patients Voice</li> </ul>	<ul> <li>National Association of Primary Care</li> </ul>
Macmillan Cancer Support	National Pharmacy Association
NA : 1 0 1	NHS Confederation
M : 0 :	Scottish Medicines Consortium
	Welsh Government
Peaches Womb Cancer Trust     South Asian Health Foundation	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
South Asian Health Foundation	Weish Health Specialised Services     Committee
Specialised Healthcare Alliance	Committee
Tenovus Cancer Care	Possible comparator companies
Wellbeing of Women	
Womb Cancer Support UK	Accord (carboplatin, paclitaxel)  Allianas Llasthagra (paclitaxel)
Women's Health Concern	Alliance Healthcare (paclitaxel)  Printed Manage Country to Plantage and the Plantage Country to Plantage and the Planta
	Bristol Myers Squibb Pharmaceuticals     (a a sliterus)
Healthcare professional groups	(paclitaxel)
Association of Anaesthetists	Consilient Health (carboplatin)
Association of Cancer Physicians	Fresenius Kabi (carboplatin, paclitaxel)
Association of Surgeons of Great	GlaxoSmithKline (dostarlimab)
Britain and Ireland	Hospira UK (carboplatin, paclitaxel)
British Association of Surgical	Pfizer (carboplatin, paclitaxel)
Oncology	Seacross Pharmaceuticals (paclitaxel)
British Geriatrics Society	Teva UK (carboplatin, paclitaxel)
British Gynaecological Cancer Society	
British Institute of Radiology	Relevant research groups
	Cochrane UK

Provisional stakeholder list for the evaluation of pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207 Issue date: March 2024



Consultees	Commentators (no right to submit or appeal)
<ul> <li>British Oncology Pharmacy Association</li> <li>British Psychosocial Oncology Society</li> <li>British Society for Clinical Cytology</li> <li>British Society for Colposcopy and Cervical Pathology</li> <li>Cancer Research UK</li> <li>National Forum of Gynaecological Oncology Nurses</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Obstetricians and Gynaecologists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul>	<ul> <li>Genomics England</li> <li>Institute of Cancer Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> </ul> Associated Public Health groups <ul> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
<ul><li>Others</li><li>Department of Health and Social Care</li><li>NHS England</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


#### **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207 Issue date: March 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.